文献速递肿瘤 PET/CT

68Ga-FAPI PET/CT 用于细胞减灭术前后腹膜癌评估

Use of 68Ga-FAPI PET/CT for Evaluation of Peritoneal Carcinomatosis Before and After Cytoreductive Surgery.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本病例来自前瞻性研究 NCT04416165,55 岁女性胰腺肿物患者同时接受 18F-FDG 与 68Ga-FAPI PET/CT 评估。68Ga-FAPI PET/CT 在肠系膜和大网膜显示比 18F-FDG 更多的异常摄取灶,疑为胰腺癌转移;细胞减灭术后病理确诊胰腺腺泡细胞癌,术后 3 个月随访 68Ga-FAPI PET/CT 示全腹部 68Ga-FAPI 活性减低,反应良好。

要点

  • 68Ga-FAPI PET/CT 较 18F-FDG 显示更多肠系膜和大网膜异常摄取灶。
  • 术后病理确诊为胰腺腺泡细胞癌。
  • 术后 3 个月 68Ga-FAPI PET/CT 示全腹部活性减低,反应良好。

核心结论

  • 68Ga-FAPI PET/CT 在腹膜癌评估中可显示比 18F-FDG 更多的异常摄取灶,并可用于术后随访评估治疗反应。

研究设计与样本

  • 前瞻性研究 NCT04416165 中的一例 55 岁女性病例。

主要发现

  • 18F-FDG 和 68Ga-FAPI PET/CT 均显示胰腺肿物伴示踪剂摄取增高。
  • 68Ga-FAPI PET/CT 在肠系膜和大网膜显示比 18F-FDG 更多的异常摄取灶,疑为胰腺癌转移。
  • 细胞减灭术后病理确诊为胰腺腺泡细胞癌。
  • 术后 3 个月随访 68Ga-FAPI PET/CT 显示全腹部 68Ga-FAPI 活性减低,反应良好。

临床怎么用

  • 对疑诊腹膜癌的胰腺肿瘤患者,可考虑 68Ga-FAPI PET/CT 辅助评估腹膜播散范围。
  • 术后可用 68Ga-FAPI PET/CT 随访评估治疗反应。

局限性

  • 本文为单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 55-year-old woman underwent 18F-FDG and 68Ga-FAPI PET/CT for tumor detection and staging under the prospective study NCT04416165. Both scans showed a mass lesion with increased tracer uptake in the pancreas. Moreover, 68Ga-FAPI PET/CT showed a greater number of abnormal foci in the mesentery and omentum than that shown with 18F-FDG. These abnormal foci were suspected to be metastases from pancreatic cancer. The patient subsequently underwent a cytoreductive surgery, and postoperative histopathology confirmed the diagnosis of acinar cell carcinoma of pancreas. Follow-up 68Ga-FAPI PET/CT (3 months after surgery) showed an excellent response with decreasing 68Ga-FAPI activity in the whole abdomen.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhao L, Pang Y, Wei J, et al. Use of 68Ga-FAPI PET/CT for Evaluation of Peritoneal Carcinomatosis Before and After Cytoreductive Surgery. Clin Nucl Med. 2021. PMID: 33782310. doi:10.1097/RLU.0000000000003611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。